Pyxis Oncology, Inc.

NASDAQ:PYXS

Biotechnology

Healthcare
$1.41 +5.53%

+$0.11 today

Market cap
$168.65M
Beta
1.43
P/E (TTM)
-1.6
EPS (TTM)
-$1.29
52W Low $0.97High $5.55

Volume 0.75M

Average 0.50M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$63.50M

FY 2025 · Annual

Investing Cash Flow

$58.86M

FY 2025 · Annual

+621.7% YoY

Financing Cash Flow

$594,000.00

FY 2025 · Annual

-99.0% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(75.98M)(120.72M)(73.79M)(77.33M)(79.62M)
Depreciation & Amortization647K709K1.93M2.98M4.51M
Deferred Income Tax6.28M0000
Stock-Based Compensation6.44M15.76M16.95M12.95M11.8M
Change in Working Capital6.68M4.5M(11.66M)(11.82M)1.94M
Accounts Receivables00000
Inventory00000
Accounts Payables4.64M(8.33M)(3.51M)1.2M6.03M
Other Working Capital2.03M12.83M(8.16M)(13.02M)(4.08M)
Other Non-Cash Items20.6M10.41M(4.13M)15.56M(2.14M)
Operating Cash Flow(35.33M)(89.34M)(70.71M)(57.67M)(63.5M)
Capital Expenditures(540K)(6.4M)(6.73M)(237K)(9K)
Acquisitions (Net)(50K)06.66M00
Purchases of Investments(50K)0(196.83M)(160.12M)(107.01M)
Sales of Investments50.05K092.05M168.51M165.87M
Other Investing Activities(50)0000
Investing Cash Flow(590K)(6.4M)(104.85M)8.16M58.86M
Debt Repayment00000
Common Stock Issued152.3M06.12M59.05M742K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities167K183K(193K)280K(148K)
Financing Cash Flow304.04M183K5.93M59.33M594K
Effect of Forex Changes00000
Net Change in Cash268.13M(95.55M)(169.63M)9.81M(4.05M)
Free Cash Flow(35.87M)(95.73M)(77.44M)(57.91M)(63.51M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$79.6M
+ D&A$4.5M
+ Stock-Based Comp$11.8M
+ Deferred Tax$0
+ Working Capital$1.9M
- Other Non-Cash-$2.1M
= Operating Cash Flow-$63.5M
- Capex-$9.0K
= Free Cash Flow-$63.5M

Analysis

FY2025 free cash flow is -$63.5M. FCF conversion is 79.8% of net income. Operating cash flow was -$63.5M, with capex of -$9.0K. The largest bridge item is Stock-Based Comp at $11.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 13, 2026
4Statement of changes in beneficial ownershipNov 6, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
SC 13G/ASC 13G/A filingNov 3, 2026

Does PYXS generate free cash flow?

Pyxis Oncology, Inc. (PYXS) generated -$63.51M of free cash flow in fiscal 2025.

How much operating cash flow does PYXS produce?

Operating cash flow was -$63.50M, before capital expenditures of $9,000.00.